Ofloxacin

Overview

Ofloxacin, sold under the brand name Floxin among others, is a quinolone antibiotic useful for the treatment of a number of bacterial infections. When taken by mouth or injection into a vein, these include pneumonia, cellulitis, urinary tract infections, prostatitis, plague, and certain types of infectious diarrhea. Other uses, along with other medications, include treating multidrug resistant tuberculosis. An eye drop may be used for a superficial bacterial infection of the eye and an ear drop may be used for otitis media when a hole in the ear drum is present.[1][2][3] WP

When taken by mouth, common side effects include vomiting, diarrhea, headache, and rash. Other serious side effect include tendon rupture, numbness due to nerve damage, seizures, and psychosis. Use in pregnancy is typically not recommended. Ofloxacin is in the fluoroquinolone family of medications. It works by interfering with the bacterium's DNA.[1][4] WP

Ofloxacin was patented in 1980 and approved for medical use in 1985. It is on the World Health Organization's List of Essential Medicines. Ofloxacin is available as a generic medication. In 2023, it was the 169th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[1][5–8] WP

Uses, dosage and effects

Medical uses

Ofloxacin is used in the treatment of bacterial infections such as: WP

• Acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) WP
• Community-acquired pneumonia WP
• Uncomplicated skin and skin structure infections WP
• Nongonococcal urethritis and cervicitis WP
• Epididymitis WP
• Mixed Infections of the urethra and cervix WP
• Acute pelvic inflammatory disease WP
• Uncomplicated cystitis WP
• Complicated urinary tract infections WP
• Prostatitis WP
• Acute, uncomplicated urethral and cervical gonorrhea WP

Ofloxacin has not been shown to be effective in the treatment of syphilis.[9] WP

Fluoroquinolones, the class of drug ofloxacin belongs to, were the drug of choice for treating gonorrhea in the 1980s; However, due to the development of fluoroquinolone-resistant Neisseria gonorrhoeae, fluoroquinolones were no longer used to treat gonorrhea by the late 1990s. As of 2004, the failure of single dose ofloxacin to treat gonorrhea has been reported in the United States, United Kingdom, Canada, and Australia.[10][11] WP

Susceptible bacteria

According to the product package insert, ofloxacin is effective against these microorganisms:[12] WP

Aerobic Gram-positive microorganisms: WP

• Staphylococcus aureus (methicillin-susceptible strains) WP
• Streptococcus pneumoniae (penicillin-susceptible strains) WP
• Streptococcus pyogenes WP

Aerobic Gram-negative microorganisms WP

• Citrobacter koseri (Citrobacter diversus) WP
• Enterobacter aerogenes WP
• Escherichia coli WP
• Haemophilus influenzae WP
• Klebsiella pneumoniae WP
• Neisseria gonorrhoeae WP
• Proteus mirabilis WP
• Pseudomonas aeruginosa WP

Other microorganisms: WP

• Chlamydia trachomatis WP

Available forms

Ofloxacin for systemic use is available in multiple strengths as a tablet, an oral suspension, and an injectable solution. It is also used as eye drops and ear drops and is available in combination with ornidazole.[13] WP

Antibiotic use and bacterial resistance

Resistance to ofloxacin and other fluoroquinolones may evolve rapidly, even during a course of treatment. Numerous pathogens, including Staphylococcus aureus, enterococci, and Streptococcus pyogenes now exhibit resistance worldwide.[14] WP

Floxacin and other fluoroquinolones had become the most commonly prescribed class of antibiotics to adults in 2002. Nearly half (42%) of these prescriptions were for conditions not approved by the US Food and Drug Administration (FDA), such as acute bronchitis, otitis media, and acute upper respiratory tract infection.[15] WP

Risks and side effects

Adverse effects

In general, fluoroquinolones are well tolerated, with most side effects being mild to moderate. On occasion, serious adverse effects occur. Common side effects include gastrointestinal effects such as nausea, vomiting, and diarrhea, as well as headache and insomnia.[16][17] WP

The overall rate of adverse events in patients treated with fluoroquinolones is roughly similar to that seen in patients treated with other antibiotic classes. A U.S. Centers for Disease Control study found patients treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin, sulfonamides, or vancomycin.[18–22] WP

Postmarketing surveillance has revealed a variety of relatively rare but serious adverse effects associated with all members of the fluoroquinolone antibacterial class. Among these, tendon problems and exacerbation of the symptoms of the neurological disorder myasthenia gravis are the subject of "black box" warnings in the United States. The most severe form of tendonopathy associated with fluoroquinolone administration is tendon rupture, which in the great majority of cases involves the Achilles tendon. Younger people typically experience good recovery, but permanent disability is possible, and is more likely in older patients. The overall frequency of fluoroquinolone-associated Achilles tendon rupture in patients treated with ciprofloxacin or levofloxacin has been estimated at 17 per 100,000 treatments. Risk is substantially elevated in the elderly and in those with recent exposure to topical or systemic corticosteroid therapy. Simultaneous use of corticosteroids is present in almost one-third of quinolone-associated tendon rupture. Tendon damage may manifest during and up to a year after fluoroquinolone therapy has been completed.[16][23–26] WP

Fluoroquinolones prolong the QT interval by blocking voltage-gated potassium channels. Prolongation of the QT interval can lead to torsades de pointes, a life-threatening arrhythmia, but in practice, this appears relatively uncommon in part because the most widely prescribed fluoroquinolones (ciprofloxacin and levofloxacin) only minimally prolong the QT interval.[27][28] WP

Clostridioides difficile-associated diarrhea may occur in connection with the use of any antibacterial drug, especially those with a broad spectrum of activity such as clindamycin, cephalosporins, and fluoroquinolones. Fluoroquinoline treatment is associated with risk similar to or less than that associated with broad spectrum cephalosporins. Fluoroquinolone administration may be associated with the acquisition and outgrowth of a particularly virulent Clostridium strain.[18][29][30][31] WP

The US prescribing information contains a warning regarding uncommon cases of peripheral neuropathy, which can be permanent. Other nervous system effects include insomnia, restlessness, and rarely, seizure, convulsions, and psychosis Other rare and serious adverse events have been observed with varying degrees of evidence for causation.[32–37] WP

Events that may occur in acute overdose are rare, and include kidney failure and seizure. Susceptible groups of patients, such as children and the elderly, are at greater risk of adverse reactions during therapeutic use.[16][38][39][40] WP

Ofloxacin, like some other fluoroquinolones, may inhibit drug-metabolizing enzymes, and thereby increase blood levels of other drugs such as cyclosporine, theophylline, and warfarin, among others. These increased blood levels may result in a greater risk of side effects. WP

Careful monitoring of serum glucose is advised when ofloxacin or other fluorquinolones are used by people who are taking sulfonylurea antidiabetes drugs. WP

The concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of central nervous system stimulation and convulsive seizures. WP

The fluoroquinolones have been shown to increase the anticoagulant effect of acenocoumarol, anisindione, and dicumarol. Additionally, the risk of cardiotoxicity and arrhythmias is increased when co-administered with drugs such as dihydroquinidine barbiturate, quinidine, and quinidine barbiturate.[41] WP

Current or past treatment with oral corticosteroids is associated with an increased risk of Achilles tendon rupture, especially in elderly patients who are also taking the fluoroquinolones.[42] WP

Contraindications

As noted above, under licensed use, ofloxacin is now considered to be contraindicated for the treatment of certain sexually transmitted diseases by some experts due to bacterial resistance. Caution should be used in people with liver disease. The excretion of ofloxacin may be reduced in patients with severe liver function disorders (e.g., cirrhosis with or without ascites). Ofloxacin is also considered to be contraindicated within the pediatric population, pregnancy, nursing mothers, patients with psychiatric illnesses and in patients with epilepsy or other seizure disorders.[43][44] WP

Pregnancy

Ofloxacin has not been shown to have any teratogenic effects at oral doses as high as 810 mg/kg/day (11 times the recommended maximum human dose based on mg/m² or 50 times based on mg/kg) and 160 mg/kg/day (four times the recommended maximum human dose based on mg/m² or 10 times based on mg/kg) when administered to pregnant rats and rabbits, respectively. Additional studies in rats with oral doses up to 360 mg/kg/day (five times the recommended maximum human dose based on mg/m2 or 23 times based on mg/kg) demonstrated no adverse effect on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the newborn. Doses equivalent to 50 and 10 times the recommended maximum human dose of ofloxacin (based on mg/kg) were fetotoxic (i.e., decreased fetal body weight and increased fetal mortality) in rats and rabbits, respectively. Minor skeletal variations were reported in rats receiving doses of 810 mg/kg/day, which is more than 10 times higher than the recommended maximum human dose based on mg/m².[45][46] WP

There are, however, no adequate and well-controlled studies in pregnant women. Ofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.[9] WP

Children

Oral and intravenous ofloxacin are not licensed for use in children, except as noted above, due to the risk of musculoskeletal injury. In one study, 1534 juvenile patients (age 6 months to 16 years) treated with levofloxacin as part of three efficacy trials were followed up to assess all musculoskeletal events occurring up to 12 months after treatment. At 12 months' follow-up, the cumulative incidence of musculoskeletal adverse events was 3.4%, compared to 1.8% among 893 patients treated with other antibiotics. In the levafloxacin-treated group, about two-thirds of these musculoskeletal adverse events occurred in the first 60 days, 86% were mild, 17% were moderate, and all resolved without long-term sequelae.[47][48] WP

In a study comparing the safety and efficacy of levofloxacin to that of azithromycin or ceftriaxone in 712 children with community-acquired pneumonia, adverse events were experienced by 6% of those treated with levofloxacin and 4% of those treated with comparator antibiotics. Most of these adverse events were thought to be unrelated or doubtfully related to the levofloxacin. Two deaths were observed in the levofloxacin group, neither of which was thought to be treatment-related. Spontaneous reports to the FDA Adverse Effects Reporting System at the time of the 20 September 2011 FDA Pediatric Drugs Advisory Committee include musculoskeletal events (39, including five cases of tendon rupture) and central nervous system events (19, including five cases of seizures) as the most common spontaneous reports between April 2005 and March 2008. An estimated 130,000 pediatric prescriptions for levofloxacin were filled on behalf of 112,000 pediatric patients during that period.[49] WP

Overdose

Limited information is available on overdose with ofloxacin. Advice for the management of an acute overdose of ofloxacin is emptying of the stomach, along with close observation, and making sure that the patient is appropriately hydrated. Hemodialysis or peritoneal dialysis is of only limited effectiveness. Overdose may result in central nervous system toxicity, cardiovascular toxicity, tendon/articular toxicity, and hepatic toxicity as well as kidney failure and seizure. Both seizures and severe psychiatric reactions have, however, been reported to occur at therapeutic dosage.[9][38][50][51][52] WP

Pharmacology

Pharmacokinetics

The bioavailability of ofloxacin in the tablet form is roughly 98% following oral administration, reaching maximum serum concentrations within one to two hours. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Therefore, elimination is mainly by renal excretion. However, 4-8% of an ofloxacin dose is excreted in the feces. This would indicate a small degree of biliary excretion, as well. Plasma elimination half-life is around 4 to 5 hours in patients and 6.4 to 7.4 hours in elderly patients.[9] WP

Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its "mirror image" or enantiomer dextrofloxacin.[53] WP

"After multiple-dose administration of 200 mg and 300 mg doses, peak serum levels of 2.2 and 3.6 μg/ml, respectively, are predicted at steady-state. In vitro, approximately 32% of the drug in plasma is protein bound. Floxin is widely distributed to body tissues. Ofloxacin has been detected in blister fluid, cervix, lung tissue, ovary, prostatic fluid, prostatic tissue, skin, and sputum. The pyridobenzoxazine ring appears to decrease the extent of parent compound metabolism. Less than 5% is eliminated by the kidneys as desmethyl or N-oxide metabolites; 4% to 8% by feces."[9][54] WP

A number of the endogenous compounds have been reported to be affected by ofloxacin as inhibitors, alteraters, and depletors. See the latest package insert for ofloxacin for additional details.[9] WP

History

History

Ofloxacin is a second-generation fluoroquinolone, being a broader-spectrum analog of norfloxacin, and was synthesized and developed by scientists at Daiichi Seiyaku.[55][56] WP

It was first approved for marketing in Japan in 1985, for oral administration, and Daiichi marketed it there under the brand name Tarvid. Daiichi, working with Johnson & Johnson, obtained FDA approval in December 1990, under the brand name Floxin, labelled for use in adults with lower respiratory tract infections, skin and skin structure infections, urinary tract infections, prostatitis, and sexually transmitted diseases. By 1991, it was also marketed as Tarvid by Hoechst in the UK, Germany, Belgium, and Portugal; as Oflocet in France, Portugal, Tunisia, and several African countries by Roussel-Uclaf, as Oflocin by Glaxo in Italy, and as Flobacin by Sigma-Tau in Italy.[56–60] WP

The market for ofloxacin was seen as difficult from its launch; it was approved as a "1C" drug, a new molecular entity with little or no therapeutic gain over existing therapies, and ciprofloxacin, which had a broader spectrum, was already on the market.[60] WP

By 1992, an intravenous solution was approved for marketing,[61] WP

In 1997, an indication for pelvic inflammatory disease was approved by the U.S. Food and Drug Administration (FDA) for the oral formulation, and in the same year, a solution for ear infections was approved under the brand[62][63] WP

Daiichi and J&J also cannibalized its own market by introducing levofloxacin, the levo-enantiomer of ofloxacin, in 1996; Johnson and Johnson's annual sales of Floxin in 2003 was about $30 million, whereas their combined sales of Levaquin/Floxin exceeded $1.15 billion in the same year. Johnson & Johnson withdrew the marketing application in 2009.[57][64][65][66] WP

Chemistry

Formula

C18H20FN3O4 PC

CAS number

82419-36-1 PC

Molar mass (g/mol)

361.4 PC

IUPAC name (computed by PubChem)

7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid PC

SMILES

CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O PC

InChIKey

GSDSWSVVBLHKDQ-UHFFFAOYSA-N PC

PubChem CID

4583

IUPAC name

(RS)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Ofloxacin
2. Other British national formulary: BNF 69. 2015
3. Other WHO Model Formulary 2008. 2009
4. Other Ofloxacin Use During Pregnancy | Drugs.com
5. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
6. Other World Health Organization model list of essential medicines: 21st list 2019. 2019
7. Other Top 300 of 2023
8. Other Ofloxacin Drug Usage Statistics, United States, 2014 - 2023
9. Journal / agency Ofloxacin tablet, film coated. 4 September 2019
10. Journal / agency Bodoev IN, Il'Ina EN. Molecular mechanisms of formation of drug resistance in Neisseria gonorrhoeae: History and prospects. Molecular Genetics, Microbiology and Virology. July 2015. doi:10.3103/S0891416815030027
11. Journal / agency Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opinion on Pharmacotherapy. April 2004. doi:10.1517/14656566.5.4.829 · PMID 15102567
12. Journal / agency Sato K, Matsuura Y, Inoue M, Une T, Osada Y, Ogawa H, Mitsuhashi S. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrobial Agents and Chemotherapy. October 1982. doi:10.1128/aac.22.4.548 · PMID 6960805 · PMC183791
13. Harm reduction site Ofloxacin
14. Other Jacobs M. International Symposium on Antimicrobial Agents and Resistance. Drugs. 2005
15. Journal / agency Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. The American Journal of Medicine. March 2005. doi:10.1016/j.amjmed.2004.09.015 · PMID 15745724
16. Journal / agency Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clinical Infectious Diseases. July 2005. doi:10.1086/428055 · PMID 15942881
17. Journal / agency De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. Current Medicinal Chemistry. March 2001. doi:10.2174/0929867013373435 · PMID 11172695
18. Journal / agency Data Mining Analysis of Multiple Antibiotics in AERS
19. Journal / agency Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clinical Microbiology and Infection. April 2013. doi:10.1111/j.1469-0691.2012.03838.x · PMID 22489673
20. Journal / agency Falagas ME, Matthaiou DK, Vardakas KZ. Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials. Mayo Clinic Proceedings. December 2006. doi:10.4065/81.12.1553 · PMID 17165634
21. Journal / agency Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Safety. 2009. doi:10.2165/00002018-200932050-00001 · PMID 19419232
22. Journal / agency Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clinical Infectious Diseases. September 2008. doi:10.1086/591126 · PMID 18694344
23. Journal / agency Kim GK. The Risk of Fluoroquinolone-induced Tendinopathy and Tendon Rupture: What Does The Clinician Need To Know?. The Journal of Clinical and Aesthetic Dermatology. April 2010. PMID 20725547 · PMC2921747
24. Journal / agency Sode J, Obel N, Hallas J, Lassen A. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. European Journal of Clinical Pharmacology. May 2007. doi:10.1007/s00228-007-0265-9 · PMID 17334751
25. Journal / agency Khaliq Y, Zhanel GG. Musculoskeletal injury associated with fluoroquinolone antibiotics. Clinics in Plastic Surgery. October 2005. doi:10.1016/j.cps.2005.05.004 · PMID 16139623
26. Journal / agency Saint F, Gueguen G, Biserte J, Fontaine C, Mazeman E. Rupture of the patellar ligament one month after treatment with fluoroquinolone. Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur. September 2000. PMID 10970974
27. Journal / agency Heidelbaugh JJ, Holmstrom H. The perils of prescribing fluoroquinolones. The Journal of Family Practice. April 2013. PMID 23570031
28. Journal / agency Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. The Journal of Antimicrobial Chemotherapy. April 2002. doi:10.1093/jac/49.4.593 · PMID 11909831
29. Journal / agency Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, Hernandez AV, Donskey CJ. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. The Journal of Antimicrobial Chemotherapy. September 2013. doi:10.1093/jac/dkt129 · PMID 23620467
30. Journal / agency Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. The Journal of Antimicrobial Chemotherapy. April 2014. doi:10.1093/jac/dkt477 · PMID 24324224
31. Journal / agency Vardakas KZ, Konstantelias AA, Loizidis G, Rafailidis PI, Falagas ME. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. International Journal of Infectious Diseases. November 2012. doi:10.1016/j.ijid.2012.07.010 · PMID 22921930
32. Journal / agency FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection
33. Journal / agency Galatti L, Giustini SE, Sessa A, Polimeni G, Salvo F, Spina E, Caputi AP. Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy. Pharmacological Research. March 2005. doi:10.1016/j.phrs.2004.08.003 · PMID 15661570
34. Journal / agency Babar SM. SIADH associated with ciprofloxacin. The Annals of Pharmacotherapy. October 2013. doi:10.1177/1060028013502457 · PMID 24259701
35. Journal / agency Rouveix B. Clinically significant toxicity and tolerance of the main antibiotics used in lower respiratory tract infections. Médecine et Maladies Infectieuses. Nov–Dec 2006. doi:10.1016/j.medmal.2006.05.012 · PMID 16876974
36. Journal / agency Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. The Annals of Pharmacotherapy. November 2007. doi:10.1345/aph.1K347 · PMID 17911203
37. Journal / agency Jones SE, Smith RH. Quinolones may induce hepatitis. BMJ. March 1997. doi:10.1136/bmj.314.7084.869 · PMID 9093098 · PMC2126221
38. Other Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA. Goldfrank's toxicologic emergencies. 2006
39. Journal / agency Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Current Medical Research and Opinion. June 2007. doi:10.1185/030079907X188099 · PMID 17559736
40. Journal / agency Farinas ER. Consult: One-Year Post Pediatric Exclusivity Postmarketing Adverse Events Review. 1 March 2005
41. Harm reduction site Showing drug card for Ofloxacin (DB01165). February 19, 2009
42. Journal / agency van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Archives of Internal Medicine. August 2003. doi:10.1001/archinte.163.15.1801 · PMID 12912715
43. Other Blank S, Schillinger J. DOHMH ALERT #8:Fluoroquinolone-resistant gonorrhea, NYC. May 14, 2004
44. Journal / agency Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I. Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection. The Annals of Pharmacotherapy. October 2005. doi:10.1345/aph.1G111 · PMID 16105873
45. Other Pharmacotherapy: Official Journal of the American College of Clinical Pharmacy Print Volume: 25 | Issue: 1 Cover date: January 2005 Page(s): 116–118 ISSN 0277-0008
46. Journal / agency Nardiello S, Pizzella T, Ariviello R. Risks of antibacterial agents in pregnancy. Le Infezioni in Medicina. March 2002. PMID 12700435
47. Journal / agency Levaquin- levofloxacin tablet, film coated. 12 July 2019
48. Journal / agency Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. The Pediatric Infectious Disease Journal. October 2007. doi:10.1097/INF.0b013e3180cbd382 · PMID 17901792
49. Journal / agency Adverse Event Review: Levaquin (levofloxacin)
50. Journal / agency Hall CE, Keegan H, Rogstad KE. Psychiatric side effects of ofloxacin used in the treatment of pelvic inflammatory disease. International Journal of STD & AIDS. September 2003. doi:10.1258/095646203322301121 · PMID 14511503
51. Journal / agency Amsden GW, Graci DM, Cabelus LJ, Hejmanowski LG. A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. Chest. July 1999. doi:10.1378/chest.116.1.115 · PMID 10424513
52. Other randomhouse author search
53. Other Ortho-McNeill, Johnson & Johnson, Daichi v. Mylan
54. Other Drugs.com. Complete Ofloxacin information from Drugs.com
55. Other Sneader W. Drug Discovery: A History. 31 October 2005
56. Journal / agency Mouton Y, Leroy O. Ofloxacin. International Journal of Antimicrobial Agents. 1991. doi:10.1016/0924-8579(91)90001-T · PMID 18611493
57. Other Atarashi S. Research and Development of Quinolones in Daiichi Sankyo Co., Ltd
58. Other LEVAQUIN Ortho-McNeil Pharmaceutical, Inc. v. Lupin Pharmaceutical, Inc. C.A. No. 06-04999-GEB-TJB May 1, 2009 Memorandum Opinion. April 2009
59. Other Benzoxazine derivatives
60. Other Johnson & Johnson Going Into 1991 With At Least Four New Product Launches: Floxin, Vascor, Procrit And Duragesic; J&J Leading Off With Procrit, Vascor. 7 January 1991
61. Journal / agency Flor SC, Rogge MC, Chow AT. Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Antimicrobial Agents and Chemotherapy. July 1993. doi:10.1128/aac.37.7.1468 · PMID 8363378 · PMC187996
62. Other Floxin Tablets (ofloxacin tablets)
63. Other Floxin otic New FDA Drug Approval
64. Other Teva Announces Approval of Ofloxacin Tablets, 200 mg, 300 mg, and 400 mg. September 2, 2003
65. Other Johnson & Johnson. Building on a foundation of health. 2003
66. Journal / agency Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications. May 19, 2009

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.